BioSpace News Archive

BD (Becton, Dickinson and Company) (NYSE: BDX), today announced the outcome of a peer-reviewed study published in the journal of Obstetrics & Gynecology that showed molecular diagnostics could improve the accuracy of vaginitis diagnosis and lead to more appropriate and timely treatment decisions.

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut.

Immunocore Holdings plc today announces approval from the United States Food and Drug Administration (FDA) of KIMMTRAK® (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM).

Tiziana Life Sciences Ltd (NASDAQ: TLSA) (“Tiziana” or the “Company”), a clinical-stage biopharmaceutical company developing breakthrough therapies for KRAS+ Non-Small Cell Lung Cancer (NSCLC) and transformational drug delivery technologies to enable alternative routes of immunotherapy, today announced its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will participate in a virtual fireside chat at the B.Riley Securities 2022 Oncology Conference.

Caraway Therapeutics today announced that the Company has been awarded a third research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Subtle’s AI Aims to Achieve a 6x Reduction in Radiation Dose of Fluoroscopy Exams.

PolyPid Ltd. today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 9, 2022.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with OrphanDC.

Hepion Pharmaceuticals, Inc. today announced the results of a nonclinical research study showing that its clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse survival when combined with an anti-PD1 antibody, an immune checkpoint inhibitor (“ICI”).

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the expansion of indications on its CORI Surgical System - the industry’s most advanced and efficient1,* handheld robotic solution in total knee arthroplasty1,*,† - to now include total hip arthroplasty (THA).